HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazuhiko Tsutsumi Selected Research

4- diethoxyphosphorylmethyl- N- (4- bromo- 2- cyanophenyl)benzamide

10/2011Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.
9/2006NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs.
7/2006Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs.
12/2005NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.
2/2005Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.
2/2004Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.
12/2003Lipoprotein lipase activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation-related enzymes in rat liver.
1/2003A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand white rabbits.
1/2003Lipoprotein lipase activator NO-1886.
7/2002A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazuhiko Tsutsumi Research Topics

Disease

9Body Weight (Weight, Body)
11/2021 - 06/2002
9Type 2 Diabetes Mellitus (MODY)
11/2021 - 08/2007
9Insulin Resistance
02/2016 - 06/2002
5Atherosclerosis
09/2006 - 01/2002
4Hyperlipidemias (Hyperlipidemia)
04/2020 - 06/2002
4Obesity
01/2015 - 12/2003
3Fatty Liver
01/2022 - 06/2002
2Inflammation (Inflammations)
01/2015 - 07/2006
1Obstructive Sleep Apnea
11/2021
1Apnea
11/2021
1Infections
05/2021
1Dyslipidemias (Dyslipidemia)
01/2021
1Muscular Diseases (Myopathy)
01/2021
1Liver Diseases (Liver Disease)
04/2020
1Arteriosclerosis
08/2007
1Diabetes Mellitus
07/2006
1Colonic Neoplasms (Colon Cancer)
02/2005
1Intestinal Polyps
02/2005
1Hypertriglyceridemia
01/2003
1Hyperinsulinism (Hyperinsulinemia)
06/2002
1Hyperglycemia
06/2002

Drug/Important Bio-Agent (IBA)

124- diethoxyphosphorylmethyl- N- (4- bromo- 2- cyanophenyl)benzamideIBA
10/2011 - 01/2002
9Lipoprotein Lipase (Diacylglycerol Lipase)IBA
10/2011 - 01/2002
8Glucose (Dextrose)FDA LinkGeneric
05/2021 - 01/2002
7LipidsIBA
11/2021 - 01/2002
6Insulin (Novolin)FDA Link
12/2018 - 01/2003
5Hemoglobins (Hemoglobin)IBA
11/2021 - 12/2018
4Sodium-Glucose Transporter 2 InhibitorsIBA
11/2021 - 12/2018
4HDL CholesterolIBA
05/2021 - 09/2006
4Blood Glucose (Blood Sugar)IBA
05/2021 - 01/2003
4Triglycerides (Triacylglycerol)IBA
04/2020 - 01/2002
4CholesterolIBA
09/2006 - 01/2002
3SymportersIBA
04/2020 - 12/2018
3SodiumIBA
04/2020 - 12/2018
3Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
02/2016 - 08/2007
3Fatty Acids (Saturated Fatty Acids)IBA
01/2015 - 08/2007
3Sucrose (Saccharose)IBA
07/2006 - 01/2002
2Messenger RNA (mRNA)IBA
01/2022 - 02/2005
2Sodium-Glucose Transport ProteinsIBA
11/2021 - 05/2021
2Uric Acid (Urate)IBA
11/2021 - 04/2020
21,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA
05/2021 - 04/2020
2Dipeptidyl-Peptidase IV InhibitorsIBA
04/2020 - 12/2018
2Peroxisome Proliferator-Activated Receptors (PPAR)IBA
02/2016 - 02/2005
1dapagliflozinIBA
01/2022
1AcidsIBA
01/2022
1Fibric Acids (Fibrates)IBA
01/2021
1Phosphotransferases (Kinase)IBA
01/2021
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2021
1(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
01/2021
1CreatinineIBA
01/2021
1Indicators and Reagents (Reagents)IBA
01/2021
1Guanosine Triphosphate (GTP)IBA
04/2020
1Hypoglycemic Agents (Hypoglycemics)IBA
12/2018
1LigandsIBA
02/2016
1Hypolipidemic Agents (Antihyperlipidemics)IBA
06/2015
1Fenofibrate (CiL)FDA LinkGeneric
06/2015
1PolyphenolsIBA
01/2015
1Pharmaceutical PreparationsIBA
10/2011
1Pioglitazone (Actos)FDA Link
10/2011
1Apolipoprotein A-I (Apolipoprotein A1)IBA
09/2006
1ATP-Binding Cassette Transporters (ABC Transporters)IBA
09/2006
1CytokinesIBA
07/2006
1Uncoupling Protein 3IBA
12/2005
1PPAR gammaIBA
02/2005
1PPAR alphaIBA
02/2005
1Streptozocin (Streptozotocin)FDA Link
02/2004
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
02/2004
1Alanine Transaminase (SGPT)IBA
02/2004
1Epoprostenol (Prostacyclin)FDA LinkGeneric
01/2003
1Prostaglandins IIBA
01/2003
1Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2003
1GlycogenIBA
06/2002
1Liver GlycogenIBA
06/2002

Therapy/Procedure

6Therapeutics
11/2021 - 10/2011
3Glycemic Control
04/2020 - 12/2018
1Continuous Positive Airway Pressure
11/2021